hide message

Welcome to the Resource Centre

We make it our mission to work with advocates in civil society, business and government to address inequalities of power, seek remedy for abuse, and ensure protection of people and planet.

Both companies and impacted communities thank us for the resources and support we provide.

This is only possible because of your support. Please make a donation today.

Thank you,
Phil Bloomer, Executive Director

Donate now hide message

Tibotec (part of Johnson & Johnson)

Tibotec website: www.tibotec.com  

🔎 Run a search for “Tibotec (part of Johnson & Johnson)”

Get RSS feed of these results

All stories

Story
1 March 2005

GlaxoSmithKline, AstraZeneca, Merck, Pfizer & other firms join UK govt. in committing to increased access to essential medicines for poorest countries, including via differential pricing

See full story

Article
1 March 2005

[PDF] Increasing people’s access to essential medicines in developing countries: a framework for good practice in the pharmaceutical industry

Author: UK Department for International Development (DFID)

Responsibility for increasing access to essential medicines rests with the whole international community...In this context there is a particular role for pharmaceutical companies. As the producers of existing, and developers of new, medicines they can...

Read more

Story
14 August 2006

Interfaith Center on Corporate Responsibility - new report on pharmaceutical firms' responses to AIDS

See full story

Article
12 September 2006

Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

Author: Compiled by Business & Human Rights Resource Centre

In August 2006, the Interfaith Center on Corporate Responsibility issued a report, "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"...The Business & Human Rights Resource Centre...

Read more

Article
1 December 2006

Pharma Companies Need to Keep Improving AIDS Response, Says ICCR and Nigerian Doctor

Author: William Baue, SocialFunds

In August 2006, the Interfaith Center on Corporate Responsibility (ICCR) produced the most thorough study of pharmaceutical company action on HIV/AIDS, documenting how the industry falls significantly short of best practice...The Business and Human...

Read more

Story
1 January 2007
+ Français - Hide
Article
1 January 2007
+ Français - Hide

Author: Les Entreprises du Médicament [France]

[annexe présente exemples d’actions & partenariats des Entreprises du Médicament: Novartis, sanofi-aventis, MSD (Merck Sharp & Dohme, partie de Merck), Laboratoires Pierre Fabre, Bayer, Novo Nordisk (partie de Novo Group), GlaxoSmithKline,...

Read more

Article
5 April 2007

Aspen to market last-resort Aids drug across Africa

Author: Samantha Enslin, Business Report [So. Africa]

Aspen plans to market a salvage treatment, Prezista, for Aids patients in 20 sub-Saharan African countries through a deal with Ireland's Tibotec Pharmaceuticals [a division of Johnson & Johnson (J&J)]...The deal was structured so that Aspen...

Read more

Article
11 March 2008

Microbicide Developer Receives License for Novel HIV Microbicide Candidate from Merck & Co., Inc.

Author: International Partnerships for Microbicides

…Merck & Co., Inc., has agreed to provide a royalty-free license to the non-profit International Partnership for Microbicides (IPM) to develop a novel antiretroviral compound for use as a potential vaginal microbicide…“Merck deserves recognition...

Read more

Article
5 June 2008

Boehringer, Gilead Freeze Antiretroviral Prices for Some U.S. Agencies [USA]

Author: Kaiser Daily HIV/AIDS Report [USA]

Pharmaceutical companies Boehringer Ingelheim and Gilead Sciences are freezing the prices of their antiretroviral drugs for select agencies in the U.S..."We urge the other drug companies to follow [Boehringer's] and Gilead's lead and to freeze price...

Read more